The PRIMA retinal implant has received European approval, becoming the first commercially available retinal implant to restore functional central vision in patients with geographic atrophy.
PRIMA Retinal Implant Receives EU Approval for Vision Restoration
The PRIMA retinal implant has received European Union (EU) approval, marking a major breakthrough in vision restoration technology for people living with geographic atrophy caused by age-related macular degeneration (AMD). The approval allows the innovative retinal implant to become commercially available across more than 30 European countries, offering new hope to patients who have lost their central vision.
Developed by Science Corporation, the PRIMA retinal implant is the first commercially approved retinal prosthesis specifically designed to restore functional central vision in patients with advanced geographic atrophy. The system combines a tiny wireless implant placed beneath the retina with a pair of specialized smart glasses equipped with a miniature camera. Together, they capture visual information and transmit it to the implant using near-infrared light, allowing the brain to interpret visual signals.
Unlike conventional treatments that primarily aim to slow the progression of vision loss, the PRIMA retinal implant is designed to restore useful sight. Clinical studies involving 38 patients showed that 84 percent of participants regained the ability to recognize letters, numbers, and words without affecting their remaining natural peripheral vision. The technology currently provides black-and-white central vision within a limited field of view, but researchers believe future versions will deliver higher resolution and even color vision.
The PRIMA system has been developed for patients suffering from geographic atrophy, an advanced form of dry age-related macular degeneration that damages the retina’s central vision. The condition affects hundreds of thousands of people worldwide and significantly impacts everyday activities such as reading, recognizing faces, and navigating independently.
Following the CE Mark approval, the first commercial procedures are expected to begin in Germany, with additional European countries expected to follow after reimbursement approvals and hospital onboarding. Science Corporation is also working with the U.S. Food and Drug Administration (FDA) to expand access to the technology in the United States.
Medical experts describe the approval as a significant milestone in the field of neurotechnology and ophthalmology. The PRIMA retinal implant demonstrates how brain-computer interface technology can restore functional vision and improve quality of life for people affected by degenerative eye diseases.
As research continues, scientists hope to further enhance the implant’s visual performance through improved image resolution, wider fields of view, and color perception. The success of PRIMA is also expected to accelerate innovation in retinal prosthetics and other vision restoration technologies, opening new possibilities for treating blindness in the future
